Acute myeloid leukemia: 2014 update on risk-stratification and management. - sprookjes - yvandenbroek - TriplyDB

Acute myeloid leukemia: 2014 update on risk-stratification and management.

Acute myeloid leukemia: 2014 update on risk-stratification and management.

http://www.wikidata.org/entity/Q34665691

about

Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells Cap-Independent Translation in Hematological Malignancies 'Acute myeloid leukemia: a comprehensive review and 2016 update'RUNX1 truncation resulting from a cryptic and novel t(6;21)(q25;q22) chromosome translocation in acute myeloid leukemia: A case report Novel ZEB2-BCL11B Fusion Gene Identified by RNA-Sequencing in Acute Myeloid Leukemia with t(2;14)(q22;q32)Prophylactic Measures During Induction for Acute Myeloid Leukemia.Future prospects of therapeutic clinical trials in acute myeloid leukemia.Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.Clinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemia Identification of an orally available compound with potent and broad FLT3 inhibition activity Low expression of microRNA-204 (miR-204) is associated with poor clinical outcome of acute myeloid leukemia (AML) patients.Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse.A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220.Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors.Hematogones: a sensitive prognostic factor for Chinese adult patients with acute myeloid leukemia Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia A three-gene expression-based risk score can refine the European LeukemiaNet AML classification.Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemia Alantolactone selectively ablates acute myeloid leukemia stem and progenitor cells.The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy.Targeting prohibitins induces apoptosis in acute myeloid leukemia cells.Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia Targeting novel signaling pathways for resistant acute myeloid leukemia.Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects.Proteogenomics approaches for studying cancer biology and their potential in the identification of acute myeloid leukemia biomarkers.Frontline treatment of acute myeloid leukemia in adults.Higher body mass index in 16-19 year-old Jewish Adolescents of North African, Middle Eastern and European Origins is a Predictor of Acute Myeloid Leukemia: a cohort of 2.3 million Israelis.Selecting Sample Preparation Workflows for Mass Spectrometry-Based Proteomic and Phosphoproteomic Analysis of Patient Samples with Acute Myeloid Leukemia KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.Diptoindonesin G promotes ERK-mediated nuclear translocation of p-STAT1 (Ser727) and cell differentiation in AML cells.Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice.An adjuvanted whole cell vaccine as post-remission immunotherapy for acute leukemia.Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia.Outcomes of 1st Remission Induction Chemotherapy in Acute Myeloid Leukemia Cytogenetic Risk Groups Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular Mechanisms DNA Methylation Events as Markers for Diagnosis and Management of Acute Myeloid Leukemia and Myelodysplastic Syndrome.Expression of the miR-148/152 Family in Acute Myeloid Leukemia and its Clinical Significance.Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis.

P2860

Q26751011-23092A2E-2300-4CD6-AA92-8649B201910B Q26770568-B7FF5E45-0E2E-4B04-9C3F-F5FE09FF9F53 Q28072539-D7E3B5AC-1146-451B-A8CF-F2C6CF72C5F3 Q28597831-E8654495-0496-4EB4-8955-267B75F7C6D7 Q28646898-CBC0E07F-335B-4190-B54E-8E5CDA311DD9 Q30235496-5C82E2F4-A081-4499-B3B3-6D674929A17B Q30244168-70E48E3F-7B13-4D05-BCF8-08486700D401 Q33555287-E616A1D2-01F3-4443-91FA-E456C0D0B487 Q33767026-10F20B9E-F775-48D5-AEA9-E2E57235938D Q35604619-C34645DC-9EE2-4B86-8206-6350FE6D4FE1 Q35789739-3CD3A373-7335-4C86-9F47-ABE280D52403 Q35869716-89E85D01-C3A4-46FC-B9A0-9B67DD9E642E Q36075433-8A6573AA-02F2-40E9-9308-AD852F74527E Q36322776-F7F11A28-AF72-4CDB-B165-AA4899DA9818 Q36408534-12EA2990-1B89-42DF-AE13-DE8B949A0513 Q36557537-767E3FE8-BC24-4C79-8C29-C583C4904D9D Q36807934-058885CB-150B-493C-8465-A596B3F4BB99 Q37140477-398FD78E-86C4-4563-AEA6-26E38935050B Q37228655-DD0005BE-596B-4AFA-8681-CFE3A139B86A Q37252482-42238FA3-F55F-4793-A8E8-3E3BE2EB3FF3 Q37278653-121CA828-1430-4D1F-8065-816CE23AEC46 Q37605585-91B8BAEE-F4AF-44AB-B161-1E8D50F474D6 Q37662175-C67C457A-C8F3-47A7-916F-66D1D74CE293 Q37744812-562C6985-A6B1-4F70-BDA8-2CF95AD5B520 Q38297507-AA8FD9EF-F660-468B-8AC7-32D73A2D3B7D Q38568355-61CADD37-448B-4264-AC78-A96122C3E775 Q38660073-B37D294D-9A9C-4790-9EB9-EA8D214808A1 Q38767583-39F8892C-E6E9-4532-9053-51C9D7F83C62 Q38930269-C71700F7-EDF5-4CAE-84DE-8BEA5911666E Q39156071-DCE1B1B3-88F2-4D4E-878C-5886A60EC614 Q40963604-B70035D7-FEC4-42E9-B485-219DAFEC122E Q41082461-3DA89783-39C1-496F-8076-846DFE21299A Q41360967-2BDBDE34-3D2B-4B20-97C1-1D1FBC952E39 Q41593302-74BFBD5A-38A2-4965-8013-22DDAFE4B9E3 Q41674738-984FB98B-0F32-4481-92E7-664A67AAA2AC Q41983363-FE1B4FCB-E532-4463-AA7A-0EF182B97148 Q42262053-62B15227-73FA-48BE-B20A-5D12D4DBF3F2 Q42361215-C0150149-1A12-4EDC-BA01-C8F7829D9346 Q42376720-AE06E84E-6A82-4D41-AC1C-35D44021A134 Q42376734-FD4317E6-5BC8-41EB-8869-B9B7A82E08DF

P2860

Acute myeloid leukemia: 2014 update on risk-stratification and management.

http://www.wikidata.org/entity/Q34665691

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Acute myeloid leukemia: 2014 update on risk-stratification and management.

@ast

Acute myeloid leukemia: 2014 update on risk-stratification and management.

@en

Acute myeloid leukemia: 2014 update on risk-stratification and management.

@nl

type

label

Acute myeloid leukemia: 2014 update on risk-stratification and management.

@ast

Acute myeloid leukemia: 2014 update on risk-stratification and management.

@en

Acute myeloid leukemia: 2014 update on risk-stratification and management.

@nl

prefLabel

Acute myeloid leukemia: 2014 update on risk-stratification and management.

@ast

Acute myeloid leukemia: 2014 update on risk-stratification and management.

@en

Acute myeloid leukemia: 2014 update on risk-stratification and management.

@nl

P1433

Q34665691-D1DD6624-6430-45EE-8F56-99575D4B889F

P1476

Q34665691-FE3DF9D3-C7DD-4667-8F1A-DA94A575AC5E

P2093

Q34665691-C265333A-C8AF-46D7-8C31-8342C243E617

P2860

Q34665691-00373E8A-A09A-42E3-8021-0192E0DBD9E8

Q34665691-0334868E-DAB6-4A45-92F9-5E2A58DB1A62

Q34665691-0A7F736E-78FF-4D89-AD30-E9CE91C2158A

Q34665691-0B0A68BF-D00E-489B-A38C-7C636A83E266

Q34665691-0B246607-CD5D-45F2-BE67-0F5B3B664616

Q34665691-0F00B526-8D9C-4AA7-9E65-7DC66C3BC7E0

Q34665691-0F96A754-2D7A-4444-947C-625053CE04BE

Q34665691-13EB9232-C546-46A0-B2B0-F099FE176A61

Q34665691-13FE3447-5CFD-4809-B2B3-FB95B9665C6D

Q34665691-1CEC4AF8-AC75-4D54-BD61-AF7E42212768

P304

Q34665691-95BBC406-9363-4583-9507-B17FE80AA0A1

P31

Q34665691-E83C17ED-1DE2-4A9A-BB08-177CAA6A893D

P356

Q34665691-4B60B2E9-E53B-4A9A-A734-1A5D429B911A

P433

Q34665691-1740F7DE-1385-4186-9A94-56EB1B64AFE6

P478

Q34665691-69EB8FBD-B566-400E-98C4-4F3AAD8A5CCA

P577

Q34665691-87878CE6-1B19-4EFF-9AA5-DE5EBE77A533

P698

Q34665691-47AC5135-CE66-4432-BCBD-2E0EC67EC7C0

P921

Q34665691-7FB74E46-1B31-4B19-BDB9-29B800BAF40F

P356

P1433

American Journal of Hematology

P1476

Acute myeloid leukemia: 2014 update on risk-stratification and management.

@en

P2093

Elihu H Estey

http://www.w3.org/2001/XMLSchema#string

P2860

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia.

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation.

Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study

P304

1063-1081

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJH.23834

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

89

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25318680

http://www.w3.org/2001/XMLSchema#string

P921